-- ChemoCentryx retains all rights in the United States and China ; Vifor Pharma gains additional marketing rights in Asia , including Japan and Middle Eastern markets -- -- ChemoCentryx to receive additional USD 20 million upfront cash commitment plus royalties on potential net sales -- --
-- Company Initiates Phase III "ADVOCATE" Clinical Trial for Complement Receptor Inhibitor Avacopan in ANCA Vasculitis; Development Path Outlined in Rare Kidney Disease for Chemokine Receptor Inhibitor ‘CCX140' -- MOUNTAIN VIEW, Calif. , Jan. 09, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif. , Jan. 04, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 35 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 12:00 p.m. PT .
- ChemoCentryx to retain commercialization rights in the United States and China , Vifor Pharma gains rights in all other markets - - ChemoCentryx to receive upfront cash commitment of USD 50 million plus potential milestones and royalties - - Vifor Pharma receives an option to develop and
-- Preparing for the Initiation of Phase III Development with Complement 5a Receptor Inhibitor Avacopan (CCX168) for the Treatment of ANCA Vasculitis -- -- Reported Positive Data from Ongoing Pilot Phase II Trial of Avacopan in Patients with Atypical Hemolytic Uremic Syndrome -- -- Highlighted
-- Oral presentation at the American Society of Nephrology (ASN) Kidney Week 2016 to highlight Phase II AAV CLEAR trial results -- -- Oral presentation at the American College of Rheumatology (ACR) 2016 Annual Meeting to highlight Phase II AAV CLASSIC trial results -- MOUNTAIN VIEW, Calif. , Nov.
MOUNTAIN VIEW, Calif. , Oct. 28, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's third quarter 2016 financial results will be released after market close on Monday, November 7, 2016 . ChemoCentryx executive management will host a conference call
MOUNTAIN VIEW, Calif. , Oct. 20, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that effective October 17, 2016 , Henry A. McKinnell , Jr, Ph.D., retired chairman and chief executive officer of Pfizer Inc., has been appointed to the Company's Board of Directors.